未登录

Y

Yani Hu

department of pharmacy

H指数:6

被引数:134

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective

替沃扎尼对比索拉非尼作为晚期肾细胞癌后续线疗法：一项基于美国医疗保健视角的成本效益分析

Risk Management and Healthcare Policy

IF2

2026-07-230

OAAI

Efficacy and Safety of Clobazam Adjunctive Therapy in Pediatric Patients with Drug-Resistant Epilepsy

氯巴扎姆辅助治疗在药物难治性癫痫儿科患者中的有效性与安全性

Drug Design; Development and Therapy

IF0

2025-12-090

OAAI

Optimising Beyond-Use Date Management and Workload to Reduce Intravenous Medication Errors: A Targeted Intervention Study

JOURNAL OF CLINICAL NURSING

IF3.5

2025-03-010

PRE

Therapeutic Drug Monitoring for Lacosamide in Chinese Pediatric Patients with Epilepsy: Focus on Clinical Effectiveness, Tolerability and Drug Interactions

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

IF3.2

2025-02-110

OAAI

Which is the most cost-effective antiseizure medication for initial monotherapy for focal epilepsy?

对于局灶性癫痫的初始单药治疗，哪种抗癫痫药物最具成本效益？

IF6.6

2025-01-220

PRE

Evaluation of the Relationship Between BDNF Val66Met Gene Polymorphism and Attention Deficit Hyperactivity Disorder: A Meta-Analysis

FRONTIERS IN PSYCHIATRY

IF3.2

2022-04-285

OAAI